Henry Schein Inc.
Henry Schein, Inc. (HSIC)
Overview
Henry Schein, Inc. is the world's largest provider of health care solutions to office-based dental and medical practitioners, operating within the Medical Distribution industry of the Healthcare sector. Founded in Queens, New York in 1932 and now headquartered in Melville, New York, the company has grown from a single pharmacy into a global distribution and technology company serving customers in more than 30 countries. Henry Schein employs roughly 25,000 people worldwide and generates approximately $13.6 billion in trailing twelve-month revenue, ranking 333rd on the 2025 Fortune 500 list and 34th among healthcare companies. The stock has traded on NASDAQ under the ticker HSIC since its 1995 IPO.
What They Do & How They Make Money
Henry Schein's core business is distribution: it buys dental and medical consumables, equipment, pharmaceuticals, and other supplies from manufacturers in bulk and resells them to hundreds of thousands of dental practices, physician offices, laboratories, ambulatory surgery centers, government clinics, and other institutional healthcare providers. The company earns money primarily on distribution margins across a catalog of hundreds of thousands of branded and Henry Schein-private-label products, supplemented by volume rebates from suppliers. Beyond pure distribution, Henry Schein layers on higher-margin, sticky revenue streams: practice management and e-services software (through Henry Schein One) that dental and medical offices pay for on a subscription basis, financial services and equipment financing for practitioners, consulting and value-added services (equipment repair, practice transitions, revenue-cycle support), and specialty manufacturing of its own dental implants, biomaterials, and orthodontic products. This combination lets Henry Schein act less like a pure middleman and more like an integrated partner that helps small, independent practices run their businesses — a relationship that drives repeat purchasing and customer loyalty over the low-margin transactional alternative of practices buying directly from manufacturers.
Business Segments
Henry Schein organizes its business into three principal operating groups:
- Global Distribution and Value-Added Services — By far the largest segment by revenue, this is the traditional distribution business supplying dental and medical consumable products, laboratory products, large equipment, and pharmaceuticals, plus value-added services such as equipment repair, financial services, and practice consulting. This segment underpins the vast majority of company-wide revenue.
- Global Specialty Products — Manufactures and markets specialty dental products, including implants, biomaterials (bone grafting and regenerative materials), and orthodontic products, largely through its majority stake in BioHorizons/Implant Direct-related businesses and other specialty brands. This is a higher-margin, faster-growing segment relative to core distribution.
- Global Technology — Develops and sells practice management software, revenue-cycle and patient-engagement tools, and other e-services (largely under the Henry Schein One brand, a joint venture-derived platform) to dental and, increasingly, medical practices. Though smaller in absolute revenue, this segment carries software-like margins and is viewed by management as a key long-term growth and retention driver.
The company also previously operated an Animal Health segment, which it spun off in 2019 as the independent, publicly traded Covetrus, narrowing Henry Schein's focus to the dental and medical (human health) markets.
Competitors
- Dental distribution: Patterson Companies (PDCO) is Henry Schein's largest direct competitor in dental distribution in the U.S.; Benco Dental (privately held) is another significant national competitor, alongside numerous regional and specialty dental distributors.
- Dental specialty/manufacturing: Envista Holdings, Dentsply Sirona, Align Technology (clear aligners), Straumann, and Zimmer Biomet's dental unit compete in implants, orthodontics, and dental equipment/consumables manufacturing.
- Medical distribution: McKesson, Cardinal Health, and AmerisourceBergen (Cencora) are much larger diversified healthcare distributors that overlap with Henry Schein in physician-office and medical-supply distribution, though their core business is pharmaceutical distribution at far greater scale.
- Practice management software: Various dental- and medical-practice software vendors (e.g., Dentrix and Eaglesoft owners, Curve Dental, athenahealth for medical practices) compete with Henry Schein One.
Competitive Position
Henry Schein's primary moat is scale and breadth: its enormous catalog, direct relationships with virtually every major dental and medical manufacturer, and logistics network let it serve small independent practices more efficiently than those practices could source products themselves, while its national footprint gives it negotiating leverage with suppliers that smaller regional distributors lack. Decades of relationship-building with independent practitioners — reinforced by financing, technology, and consulting services that increase switching costs — create a "one-stop-shop" value proposition that pure product distributors cannot easily replicate. The company's specialty products and technology segments provide higher-margin diversification against the historically thin margins of core distribution.
Key risks include continued consolidation of independent dental and medical practices into larger dental service organizations (DSOs) and hospital systems, which often negotiate directly with manufacturers or larger group-purchasing organizations and can bypass traditional distributors, compressing Henry Schein's addressable market and pricing power. The company also faces margin pressure from e-commerce-driven price transparency, cybersecurity risk (Henry Schein suffered a significant ransomware/cyberattack in 2023 that disrupted operations), and macro sensitivity to elective dental/medical procedure volumes, which softened post-pandemic and contributed to a mild revenue decline in 2023 before growth resumed in 2024–2026. Ongoing integration of specialty and technology acquisitions, and reliance on stable relationships with a concentrated set of major suppliers, are additional watch items for investors.